COREG CR (carvedilol phosphate) by Viatris (2) is β-adrenoreceptor blocking activity is present in the s(-) enantiomer and α 1 -adrenergic blocking activity is present in both r(+) and s(-) enantiomers at equal potency. Approved for hypertension. First approved in 2006.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
COREG CR is an extended-release oral capsule formulation of carvedilol phosphate, a non-selective beta-blocker with alpha-1 blocking activity. It is indicated for hypertension and pre-hypertension management. The drug works by blocking both β-adrenergic and α-1 adrenergic receptors, reducing sympathetic outflow and peripheral resistance.
Post-LOE lifecycle with minimal Part D spending ($529K, 2023) signals a mature, legacy product with reduced team investment and limited growth opportunities.
β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α 1 -adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity.
Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components
Worked on COREG CR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
COREG CR shows zero linked job openings, reflecting its post-LOE status and minimal commercial investment. Career opportunities on this brand are severely limited, with most roles focused on defending declining market share against generics and biosimilar-equivalent competitors.